%0 Journal Article
%T Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas
%A Dorthe Schaue
%A Mi-Heon Lee
%A Philippe Nickers
%A Simone P. Niclou
%A Tania Kaprealian
%A William H. McBride
%J Archive of "Advances in Radiation Oncology".
%D 2019
%R 10.1016/j.adro.2018.11.005
%X Glioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for immunotherapy. However, GBM tends to be nonimmunogenic and exhibits a microenvironment with few or no effector T cells, a relatively low nonsynonymous somatic mutational load, and a low predicted neoantigen burden. GBM also exploits a multitude of immunosuppressive strategies
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460102/